Patents by Inventor Fathia Mami-Chouaib

Fathia Mami-Chouaib has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-NEUROPILIN-1 AND ANTI-PROGRAMMED CELL DEATH-1 COMBINATION THERAPY FOR TREATING CANCER
    Publication number: 20220023342
    Abstract: The present invention relates to the combined use of a neuropilin-1 (Nrp-1) neutralizing agent and of a programmed cell death-1 (PD-1) neutralizing agent for killing cancer cells, typically for treating cancer, as well as to corresponding pharmaceutical compositions and kits, and to corresponding diagnostic and therapeutic methods. The invention further relates to in vitro, ex vivo and in vivo methods for detecting CD8+ TILs capable of recognizing cancer cells, for predicting the response of a subject to anti-PD-1 treatment of cancer, and for identifying a subject who responds therapeutically to a treatment of cancer with an antibody combination therapy comprising anti-Nrp-1 and anti-PD-1 antibodies.
    Type: Application
    Filed: December 2, 2019
    Publication date: January 27, 2022
    Inventors: FATHIA MAMI-CHOUAIB, MARINE LECLERC, GEORGES BISMUTH
  • Immunogenic preprocalcitonin peptides
    Patent number: 11179449
    Abstract: The invention relates to combinations of peptides carrying T-cell epitopes of the antigen preprocalcitonin, presented by the MHC. These peptides can be used in anti-tumour immunotherapy.
    Type: Grant
    Filed: July 4, 2016
    Date of Patent: November 23, 2021
    Assignees: Institut Gustave Roussy, Institut National de la Sante et de la Recherche Medicale, Université Paris-Saclay
    Inventors: Fathia Mami-Chouaib, Aurélie Durgeau
  • Immunogenic Preprocalcitonin Peptides
    Publication number: 20180200355
    Abstract: The invention relates to combinations of peptides carrying T-cell epitopes of the antigen preprocalcitonin, presented by the MHC. These peptides can be used in anti-tumour immunotherapy.
    Type: Application
    Filed: July 4, 2016
    Publication date: July 19, 2018
    Applicant: Institut Gustave Roussy
    Inventors: Fathia Mami-Chouaib, Aurélie Durgeau
  • Preprocalcitonin antigen T epitopes
    Patent number: 8492342
    Abstract: The present invention is related to Preprocalcitonin antigen T epitopes, presented by the Major Histocompatibility Complex I (MHC I). These peptides can be used in cancer immunotherapy.
    Type: Grant
    Filed: June 19, 2008
    Date of Patent: July 23, 2013
    Assignees: Institut Gustave Roussy, Institut National de la Sante et de la Rescherche Medicale
    Inventors: Faten El Hage, Vincent Stroobant, Pierre G. Coulie, Fathia Mami-Chouaib
  • Use of inhibitors of scinderin and/or ephrin-A1 for treating tumors
    Patent number: 8058252
    Abstract: The invention relates to the use of inhibitors of the expression or the activity of scinderin and/or of ephrin-A1 inhibitors for increasing the susceptibility of tumor cells to CTL killing. Such inhibitors may be for instance interfering RNAs targeting the scinderin gene and/or interfering RNAs targeting the ephrin-A1 gene.
    Type: Grant
    Filed: December 28, 2006
    Date of Patent: November 15, 2011
    Assignee: Institut Gustave Roussy
    Inventors: Salem Chouaib, Soraya Rifal, Catherine Gaudin, Fathia Mami-Chouaib
  • PREPROCALCITONIN ANTIGEN T EPITOPES
    Publication number: 20100184700
    Abstract: The present invention is related to Preprocalcitonin antigen T epitopes, presented by the Major Histocompatibility Complex I (MHC I). These peptides can be used in cancer immunotherapy.
    Type: Application
    Filed: June 19, 2008
    Publication date: July 22, 2010
    Inventors: Faten El Hage, Vincent Stroobant, Pierre G. Coulie, Fathia Mami-Chouaib